20/20 Gene Systems
20/20 BioLabs, formerly 2020 GeneSystems, develops and commercializes AI-powered laboratory blood tests for the early detection and prevention of cancers and chronic diseases. Their OneTest™ for Cancer is a multi-cancer early detection (MCED) blood test that detects multiple cancers at earlier stages and is priced under $200, with blood collected at home. They are also launching OneTest for Longevity, which measures biomarkers of inflammation associated with chronic diseases and offers guidance for improving health aging. The company leverages machine learning algorithms trained on extensive real-world data, with CAP Accredited & CLIA Licensed laboratories ensuring high accuracy and reliability. They have garnered support from studies by the U.S. National Cancer Institute and leading academic medical centers. The company has over 8,000 investors.
20/20 Gene Systems
20/20 BioLabs, formerly 2020 GeneSystems, develops and commercializes AI-powered laboratory blood tests for the early detection and prevention of cancers and chronic diseases. Their OneTest™ for Cancer is a multi-cancer early detection (MCED) blood test that detects multiple cancers at earlier stages and is priced under $200, with blood collected at home. They are also launching OneTest for Longevity, which measures biomarkers of inflammation associated with chronic diseases and offers guidance for improving health aging. The company leverages machine learning algorithms trained on extensive real-world data, with CAP Accredited & CLIA Licensed laboratories ensuring high accuracy and reliability. They have garnered support from studies by the U.S. National Cancer Institute and leading academic medical centers. The company has over 8,000 investors.